查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1472192

Pregabalin市場：按類型、應用、通路分類：2023-2032 年全球機會分析與產業預測

Pregabalin Market By Type, By Application, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 289 Pages | 商品交期: 2-3個工作天內

價格

2022年Pregabalin市場價值為16億美元，預計2032年將達22億美元，2023年至2032年複合年成長率為3%。Pregabalin屬於一組稱為抗驚厥藥或抗癲癇藥的藥物。癲癇、焦慮症和神經病變疼痛是Pregabalin主要治療的疾病。Pregabalin是加巴噴丁類藥物的一部分，透過調節某些神經傳導物質的活性在大腦中發揮作用。

Pregabalin最初是作為一種抗癲癇藥物開發的，後來被發現可用於治療許多神經病變疼痛疾病，包括纖維肌痛、糖尿病性神經病變和帶狀皰疹後遺症神經痛（帶狀皰疹後的神經痛） 。透過與中樞神經系統電壓門控鈣離子通道的 α2-δ次單元結合，它可以抑制 P 物質、去甲腎上腺素和麩胺酸等神經傳導物質的釋放。控制這種神經傳導物質的釋放可以減少疼痛的可能性並穩定大腦中異常的電活動。Pregabalin是一種用於治療整體焦慮症（GAD）的抗癲癇藥物。人們認為它透過抑制參與焦慮途徑的神經傳導物質（例如麩胺酸和去甲腎上腺素）的釋放來發揮抗焦慮作用。

推動市場的主要因素是神經性疼痛的盛行率迅速增加。人口老化的加劇、糖尿病盛行率的增加以及診斷技術的進步都導致神經病變疼痛疾病（例如糖尿病神經神經病變和帶狀皰疹後遺症神經痛）的盛行率迅速增加。Pregabalin的需求量很大，並且正在推動市場成長，因為它可以有效治療越來越多的患者的神經病變疼痛。

普瑞巴林市場-IMG1

癲癇是一種神經系統疾病，會導致反覆發作。此外，癲癇的發生率也急劇上升。由於獲得醫療保健的機會的改善和對該疾病的認知的提高，越來越多的人正在接受癲癇診斷和治療。癲癇患者服用抗癲癇藥物Pregabalin來控制癲癇發作，增加了對該藥物的需求並推動了市場的發展。

此外，越來越多的人患有焦慮症，推動了Pregabalin的消費。隨著Pregabalin核准用於治療廣泛性焦慮症，其市場潛力已超出了疼痛和癲癇的治療範圍。Pregabalin在治療焦慮方面的有效性和提高社會對心理健康問題的認知是推動該藥物市場擴張的因素。

此外，Pregabalin的副作用包括週邊水腫、體重增加、嗜睡和頭暈。由於潛在的誤用、依賴性和戒斷症狀等安全問題，該藥物的廣泛使用受到限制。此外，Pregabalin在市場上也面臨來自神經病變疼痛、癲癇和焦慮症替代療法的競爭，包括非藥物療法、物理治療和其他藥物。然而，隨著患者人數的增加、可支配預算的增加以及醫療保健機會的改善，新興市場為Pregabalin製造商提供了開拓的前景。定價策略的變化、分銷管道的擴張和行銷舉措等因素預計將推動市場成長。

Pregabalin市場分為類型、應用、通路和地區。按類型，市場分為錠劑/膠囊和其他。依用途分為神經病變疼痛、癲癇等。依分銷通路分類，可分為醫院藥局、藥局/零售藥局、網路藥局。

按地區分類，北美（美國、加拿大、墨西哥）、歐洲（德國、法國、英國、義大利、西班牙、其他歐洲國家地區）、亞太地區（印度、中國、日本、澳洲、韓國、其他亞太地區） ）、中國分析近東和非洲（巴西、阿根廷、哥倫比亞等亞太地區）、中東和非洲（海合會、南非、非洲等亞太地區）。

相關人員的主要利益

該報告提供了 2022 年至 2032 年Pregabalin市場分析的細分市場、當前趨勢、估計和動態的定量分析，並確定了Pregabalin市場的潛在機會。

我們提供市場研究以及與市場促進因素、市場限制和市場機會相關的資訊。

波特的五力分析強調買家和供應商幫助相關人員做出利潤驅動的商業決策並加強供應商-買家網路的潛力。

對Pregabalin市場細分的詳細分析有助於識別市場機會。

每個地區的主要國家都根據其對全球市場的收益貢獻繪製了地圖。

市場參與者定位有助於基準化分析，並提供對市場參與者當前位置的清晰了解。

該報告包括對區域和全球Pregabalin市場趨勢、主要企業、細分市場、應用領域和市場成長策略的分析。

可以使用此報告進行報告客製化（可能需要額外費用和時間表）

  • 國家、區域和全球各級的患者/流行病學資料
  • 監管指引
  • 根據客戶興趣新增其他公司簡介
  • 按國家或地區進行的附加分析 – 市場規模和預測
  • 公司簡介的擴充列表
  • 歷史市場資料
  • SWOT分析

目錄

第1章簡介

第 2 章執行摘要

第3章市場概況

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資機會
  • 波特五力分析
  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會

第4章Pregabalin市場：依類型

  • 概述
  • 錠劑和膠囊
  • 其他

第5章Pregabalin市場：依應用分類

  • 概述
  • 癲癇
  • 神經病變疼痛
  • 其他

第6章Pregabalin市場：依通路分類

  • 概述
  • 醫院藥房
  • 藥局和零售藥局
  • 線上提供者

第7章Pregabalin市場：依地區

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 其他
  • 拉丁美洲
    • 巴西
    • 哥倫比亞
    • 阿根廷
    • 其他拉丁美洲
  • 中東/非洲
    • Gcc
    • 南非
    • 北非
    • 其他中東/非洲

第8章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 2022年主要企業定位

第9章 公司簡介

  • Viatris Inc.
  • Rising Pharmaceuticals
  • Cipla
  • Lupin Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd
  • Markans Pharma Ltd.
  • Sciegen Pharmaceuticals Inc.
  • Zydus Group
  • Novartis AG
  • Amneal Pharmaceuticals LLC
Product Code: A02320

The pregabalin market was valued at $1.6 billion in 2022 and is estimated to reach $2.2 billion by 2032, exhibiting a CAGR of 3% from 2023 to 2032. Pregabalin belongs to a group of drugs known as anticonvulsants or antiepileptic drugs. Epilepsy, anxiety disorder, and neuropathic pain are the main conditions that pregabalin treats majorly. It is a member of the class of medications known as gabapentinoids, which function in the brain by modifying the activity of specific neurotransmitters.

Pregabalin was first developed as an antiepileptic medication, then it was subsequently discovered to be useful in treating a number of neuropathic pain conditions, such as fibromyalgia, diabetic neuropathy, and postherpetic neuralgia (pain in the nerves after shingles). By binding to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, it reduces the release of neurotransmitters such as substance P, noradrenaline, and glutamate. This control over the release of neurotransmitters lessens the likelihood of pain and stabilizes aberrant electrical activity in the brain. Pregabalin is used as an antiepileptic drug to treat generalized anxiety disorder (GAD). It is believed to have an anxiolytic effect by inhibiting the release of neurotransmitters, including glutamate and norepinephrine that are involved in anxiety pathways.

The major factor that drives the market is the surge in prevalence of neuropathic pain. Rise in geriatric population, an increase in the incidence of diabetes, and advancements in diagnostics have all contributed to a surge in the prevalence of neuropathic pain diseases, such as diabetic neuropathy and postherpetic neuralgia. Pregabalin is in high demand due to its efficacy in treating neuropathic pain, which is experienced by an increasing number of patients, thereby driving the growth of the market.

Pregabalin Market - IMG1

Epilepsy is a neurological illness marked by recurring seizures. Moreover, there is a surge in the incidence of epilepsy. More people receive epilepsy diagnoses and treatments as a result of greater healthcare accessibility and rise in awareness of the ailment. Patients with epilepsy are provided pregabalin, an antiepileptic treatment, to control their seizures, which increases demand for the drug, thus driving the market.

Furthermore, the rise in the number of individuals suffering from the anxiety fosters the consumption of pregabalin. With its approval for the management of GAD, the market potential of pregabalin has grown beyond the treatment of pain and epilepsy. The effectiveness of pregabalin in treating anxiety and the rise in public awareness of mental health issues are factors that drive the market expansion of this drug.

Moreover, peripheral edema, weight gain, sleepiness, and dizziness are among the side effects of pregabalin. The broad use of this medication is restricted due to safety concerns, namely pertaining to the possibility of misuse, dependence, and withdrawal symptoms. Moreover, pregabalin faces competition in the market from alternative treatments for neuropathic pain, epilepsy, and anxiety disorders, such as non-pharmacological therapies, physical therapy, and other pharmaceuticals. However, due to rise in patient population, increased disposable budgets, and improved access to healthcare, emerging markets offer pregabalin manufacturers unexplored prospects. Factors such as modifying price strategies, expanding distribution channels, and marketing initiatives are anticipated to drive market growth.

The pregabalin market is segmented into type, application, distribution channel, and region. On the basis of type, the market is bifurcated into tablet & capsules and others. On the basis of application, the market is classified into neuropathic pain, epilepsy, and others. On the basis of distribution channel, the market is categorized into hospital pharmacies, drug store & retail pharmacies, and online providers.

On the basis of region, market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and the rest of Europe), Asia-Pacific (India, China, Japan, Australia, South Korea, and rest of Asia-Pacific), and Latin America (Brazil, Argentina, Colombia, and rest of Latin America), and Middle East & Africa (GCC, South Africa, North Africa, and rest of LAMEA).

The major players that operate in the pregabalin market include Viatris Inc., Cipla, Amneal Pharmaceuticals, Rising Pharmaceutical, Teva Pharmaceutical, Lupin, ScieGen Pharmaceuticals Inc., Zydus, Medley Pharmaceuticals Ltd., and Novartis AG. The key players have adopted key strategies such as product launch to expand their product portfolio.

Key Benefits for Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the pregabalin market analysis from 2022 to 2032 to identify the prevailing pregabalin market opportunities.

The market research is offered along with information related to key drivers, restraints, and opportunities.

Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

In-depth analysis of the pregabalin market segmentation assists to determine the prevailing market opportunities.

Major countries in each region are mapped according to their revenue contribution to the global market.

Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

The report includes the analysis of the regional as well as global pregabalin market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Patient/epidemiology data at country, region, global level
  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • SWOT Analysis

Key Market Segments

By Type

  • Tablets and Capsules
  • Others

By Application

  • Epilepsy
  • Neuropathic Pain
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Drug Store and Retail Pharmacies
  • Online Providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Colombia
    • Argentina
    • Rest of Latin America
  • Middle East and Africa
    • Gcc
    • South Africa
    • North Africa
    • Rest of Middle East And Africa

Key Market Players:

    • Viatris Inc.
    • Rising Pharmaceuticals
    • Cipla
    • Lupin Pharmaceuticals
    • Teva Pharmaceutical Industries Ltd
    • Markans Pharma Ltd.
    • Sciegen Pharmaceuticals Inc.
    • Zydus Group
    • Novartis AG
    • Amneal Pharmaceuticals LLC

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
  • 3.4. Market dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: PREGABALIN MARKET, BY TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Tablets and Capsules
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Others
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country

CHAPTER 5: PREGABALIN MARKET, BY APPLICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Epilepsy
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Neuropathic Pain
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Others
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: PREGABALIN MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital Pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Drug Store and Retail Pharmacies
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Online Providers
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: PREGABALIN MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by Type
    • 7.2.3. Market size and forecast, by Application
    • 7.2.4. Market size and forecast, by Distribution Channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Market size and forecast, by Type
      • 7.2.5.1.2. Market size and forecast, by Application
      • 7.2.5.1.3. Market size and forecast, by Distribution Channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Market size and forecast, by Type
      • 7.2.5.2.2. Market size and forecast, by Application
      • 7.2.5.2.3. Market size and forecast, by Distribution Channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Market size and forecast, by Type
      • 7.2.5.3.2. Market size and forecast, by Application
      • 7.2.5.3.3. Market size and forecast, by Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by Type
    • 7.3.3. Market size and forecast, by Application
    • 7.3.4. Market size and forecast, by Distribution Channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Market size and forecast, by Type
      • 7.3.5.1.2. Market size and forecast, by Application
      • 7.3.5.1.3. Market size and forecast, by Distribution Channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Market size and forecast, by Type
      • 7.3.5.2.2. Market size and forecast, by Application
      • 7.3.5.2.3. Market size and forecast, by Distribution Channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Market size and forecast, by Type
      • 7.3.5.3.2. Market size and forecast, by Application
      • 7.3.5.3.3. Market size and forecast, by Distribution Channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Market size and forecast, by Type
      • 7.3.5.4.2. Market size and forecast, by Application
      • 7.3.5.4.3. Market size and forecast, by Distribution Channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Market size and forecast, by Type
      • 7.3.5.5.2. Market size and forecast, by Application
      • 7.3.5.5.3. Market size and forecast, by Distribution Channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Market size and forecast, by Type
      • 7.3.5.6.2. Market size and forecast, by Application
      • 7.3.5.6.3. Market size and forecast, by Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by Type
    • 7.4.3. Market size and forecast, by Application
    • 7.4.4. Market size and forecast, by Distribution Channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Market size and forecast, by Type
      • 7.4.5.1.2. Market size and forecast, by Application
      • 7.4.5.1.3. Market size and forecast, by Distribution Channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Market size and forecast, by Type
      • 7.4.5.2.2. Market size and forecast, by Application
      • 7.4.5.2.3. Market size and forecast, by Distribution Channel
      • 7.4.5.3. India
      • 7.4.5.3.1. Market size and forecast, by Type
      • 7.4.5.3.2. Market size and forecast, by Application
      • 7.4.5.3.3. Market size and forecast, by Distribution Channel
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Market size and forecast, by Type
      • 7.4.5.4.2. Market size and forecast, by Application
      • 7.4.5.4.3. Market size and forecast, by Distribution Channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Market size and forecast, by Type
      • 7.4.5.5.2. Market size and forecast, by Application
      • 7.4.5.5.3. Market size and forecast, by Distribution Channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Market size and forecast, by Type
      • 7.4.5.6.2. Market size and forecast, by Application
      • 7.4.5.6.3. Market size and forecast, by Distribution Channel
  • 7.5. Latin America
    • 7.5.1. Key market trends, growth factors and opportunities
    • 7.5.2. Market size and forecast, by Type
    • 7.5.3. Market size and forecast, by Application
    • 7.5.4. Market size and forecast, by Distribution Channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Market size and forecast, by Type
      • 7.5.5.1.2. Market size and forecast, by Application
      • 7.5.5.1.3. Market size and forecast, by Distribution Channel
      • 7.5.5.2. Colombia
      • 7.5.5.2.1. Market size and forecast, by Type
      • 7.5.5.2.2. Market size and forecast, by Application
      • 7.5.5.2.3. Market size and forecast, by Distribution Channel
      • 7.5.5.3. Argentina
      • 7.5.5.3.1. Market size and forecast, by Type
      • 7.5.5.3.2. Market size and forecast, by Application
      • 7.5.5.3.3. Market size and forecast, by Distribution Channel
      • 7.5.5.4. Rest of Latin America
      • 7.5.5.4.1. Market size and forecast, by Type
      • 7.5.5.4.2. Market size and forecast, by Application
      • 7.5.5.4.3. Market size and forecast, by Distribution Channel
  • 7.6. Middle East and Africa
    • 7.6.1. Key market trends, growth factors and opportunities
    • 7.6.2. Market size and forecast, by Type
    • 7.6.3. Market size and forecast, by Application
    • 7.6.4. Market size and forecast, by Distribution Channel
    • 7.6.5. Market size and forecast, by country
      • 7.6.5.1. Gcc
      • 7.6.5.1.1. Market size and forecast, by Type
      • 7.6.5.1.2. Market size and forecast, by Application
      • 7.6.5.1.3. Market size and forecast, by Distribution Channel
      • 7.6.5.2. South Africa
      • 7.6.5.2.1. Market size and forecast, by Type
      • 7.6.5.2.2. Market size and forecast, by Application
      • 7.6.5.2.3. Market size and forecast, by Distribution Channel
      • 7.6.5.3. North Africa
      • 7.6.5.3.1. Market size and forecast, by Type
      • 7.6.5.3.2. Market size and forecast, by Application
      • 7.6.5.3.3. Market size and forecast, by Distribution Channel
      • 7.6.5.4. Rest of Middle East And Africa
      • 7.6.5.4.1. Market size and forecast, by Type
      • 7.6.5.4.2. Market size and forecast, by Application
      • 7.6.5.4.3. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product mapping of top 10 player
  • 8.4. Competitive dashboard
  • 8.5. Competitive heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. Viatris Inc.
    • 9.1.1. Company overview
    • 9.1.2. Key executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. Rising Pharmaceuticals
    • 9.2.1. Company overview
    • 9.2.2. Key executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
    • 9.2.7. Key strategic moves and developments
  • 9.3. Cipla
    • 9.3.1. Company overview
    • 9.3.2. Key executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. Lupin Pharmaceuticals
    • 9.4.1. Company overview
    • 9.4.2. Key executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
    • 9.4.7. Key strategic moves and developments
  • 9.5. Teva Pharmaceutical Industries Ltd
    • 9.5.1. Company overview
    • 9.5.2. Key executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
    • 9.5.7. Key strategic moves and developments
  • 9.6. Markans Pharma Ltd.
    • 9.6.1. Company overview
    • 9.6.2. Key executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
    • 9.6.7. Key strategic moves and developments
  • 9.7. Sciegen Pharmaceuticals Inc.
    • 9.7.1. Company overview
    • 9.7.2. Key executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
    • 9.7.7. Key strategic moves and developments
  • 9.8. Zydus Group
    • 9.8.1. Company overview
    • 9.8.2. Key executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
    • 9.8.7. Key strategic moves and developments
  • 9.9. Novartis AG
    • 9.9.1. Company overview
    • 9.9.2. Key executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
    • 9.9.7. Key strategic moves and developments
  • 9.10. Amneal Pharmaceuticals LLC
    • 9.10.1. Company overview
    • 9.10.2. Key executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance
    • 9.10.7. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 02. PREGABALIN MARKET FOR TABLETS AND CAPSULES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. PREGABALIN MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. GLOBAL PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 05. PREGABALIN MARKET FOR EPILEPSY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 06. PREGABALIN MARKET FOR NEUROPATHIC PAIN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. PREGABALIN MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. GLOBAL PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 09. PREGABALIN MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. PREGABALIN MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. PREGABALIN MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. PREGABALIN MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. NORTH AMERICA PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA PREGABALIN MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 17. U.S. PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 18. U.S. PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 19. U.S. PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 20. CANADA PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 21. CANADA PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 22. CANADA PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 23. MEXICO PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 24. MEXICO PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 26. EUROPE PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 27. EUROPE PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE PREGABALIN MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 30. GERMANY PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 31. GERMANY PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 32. GERMANY PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 33. FRANCE PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 34. FRANCE PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 35. FRANCE PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 36. UK PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 37. UK PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 38. UK PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 39. ITALY PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 40. ITALY PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 41. ITALY PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 42. SPAIN PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 43. SPAIN PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 44. SPAIN PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 45. REST OF EUROPE PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 46. REST OF EUROPE PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 47. REST OF EUROPE PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 48. ASIA-PACIFIC PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 49. ASIA-PACIFIC PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 50. ASIA-PACIFIC PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 51. ASIA-PACIFIC PREGABALIN MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 52. JAPAN PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 53. JAPAN PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 54. JAPAN PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 55. CHINA PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 56. CHINA PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 57. CHINA PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 58. INDIA PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 59. INDIA PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 60. INDIA PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 61. AUSTRALIA PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 62. AUSTRALIA PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 63. AUSTRALIA PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 64. SOUTH KOREA PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 65. SOUTH KOREA PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 66. SOUTH KOREA PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 67. REST OF ASIA-PACIFIC PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 68. REST OF ASIA-PACIFIC PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 70. LATIN AMERICA PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 71. LATIN AMERICA PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 72. LATIN AMERICA PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 73. LATIN AMERICA PREGABALIN MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 74. BRAZIL PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 75. BRAZIL PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 76. BRAZIL PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 77. COLOMBIA PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 78. COLOMBIA PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 79. COLOMBIA PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 80. ARGENTINA PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 81. ARGENTINA PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 82. ARGENTINA PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 83. REST OF LATIN AMERICA PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 84. REST OF LATIN AMERICA PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 85. REST OF LATIN AMERICA PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 86. MIDDLE EAST AND AFRICA PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 87. MIDDLE EAST AND AFRICA PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 88. MIDDLE EAST AND AFRICA PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 89. MIDDLE EAST AND AFRICA PREGABALIN MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 90. GCC PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 91. GCC PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 92. GCC PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 93. SOUTH AFRICA PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 94. SOUTH AFRICA PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 95. SOUTH AFRICA PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 96. NORTH AFRICA PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 97. NORTH AFRICA PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 98. NORTH AFRICA PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 99. REST OF MIDDLE EAST AND AFRICA PREGABALIN MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 100. REST OF MIDDLE EAST AND AFRICA PREGABALIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 101. REST OF MIDDLE EAST AND AFRICA PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 102. VIATRIS INC.: KEY EXECUTIVES
  • TABLE 103. VIATRIS INC.: COMPANY SNAPSHOT
  • TABLE 104. VIATRIS INC.: PRODUCT SEGMENTS
  • TABLE 105. VIATRIS INC.: SERVICE SEGMENTS
  • TABLE 106. VIATRIS INC.: PRODUCT PORTFOLIO
  • TABLE 107. VIATRIS INC.: KEY STRATERGIES
  • TABLE 108. RISING PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 109. RISING PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 110. RISING PHARMACEUTICALS: PRODUCT SEGMENTS
  • TABLE 111. RISING PHARMACEUTICALS: SERVICE SEGMENTS
  • TABLE 112. RISING PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 113. RISING PHARMACEUTICALS: KEY STRATERGIES
  • TABLE 114. CIPLA: KEY EXECUTIVES
  • TABLE 115. CIPLA: COMPANY SNAPSHOT
  • TABLE 116. CIPLA: PRODUCT SEGMENTS
  • TABLE 117. CIPLA: SERVICE SEGMENTS
  • TABLE 118. CIPLA: PRODUCT PORTFOLIO
  • TABLE 119. CIPLA: KEY STRATERGIES
  • TABLE 120. LUPIN PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 121. LUPIN PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 122. LUPIN PHARMACEUTICALS: PRODUCT SEGMENTS
  • TABLE 123. LUPIN PHARMACEUTICALS: SERVICE SEGMENTS
  • TABLE 124. LUPIN PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 125. LUPIN PHARMACEUTICALS: KEY STRATERGIES
  • TABLE 126. TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY EXECUTIVES
  • TABLE 127. TEVA PHARMACEUTICAL INDUSTRIES LTD: COMPANY SNAPSHOT
  • TABLE 128. TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT SEGMENTS
  • TABLE 129. TEVA PHARMACEUTICAL INDUSTRIES LTD: SERVICE SEGMENTS
  • TABLE 130. TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT PORTFOLIO
  • TABLE 131. TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY STRATERGIES
  • TABLE 132. MARKANS PHARMA LTD.: KEY EXECUTIVES
  • TABLE 133. MARKANS PHARMA LTD.: COMPANY SNAPSHOT
  • TABLE 134. MARKANS PHARMA LTD.: PRODUCT SEGMENTS
  • TABLE 135. MARKANS PHARMA LTD.: SERVICE SEGMENTS
  • TABLE 136. MARKANS PHARMA LTD.: PRODUCT PORTFOLIO
  • TABLE 137. MARKANS PHARMA LTD.: KEY STRATERGIES
  • TABLE 138. SCIEGEN PHARMACEUTICALS INC.: KEY EXECUTIVES
  • TABLE 139. SCIEGEN PHARMACEUTICALS INC.: COMPANY SNAPSHOT
  • TABLE 140. SCIEGEN PHARMACEUTICALS INC.: PRODUCT SEGMENTS
  • TABLE 141. SCIEGEN PHARMACEUTICALS INC.: SERVICE SEGMENTS
  • TABLE 142. SCIEGEN PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
  • TABLE 143. SCIEGEN PHARMACEUTICALS INC.: KEY STRATERGIES
  • TABLE 144. ZYDUS GROUP: KEY EXECUTIVES
  • TABLE 145. ZYDUS GROUP: COMPANY SNAPSHOT
  • TABLE 146. ZYDUS GROUP: PRODUCT SEGMENTS
  • TABLE 147. ZYDUS GROUP: SERVICE SEGMENTS
  • TABLE 148. ZYDUS GROUP: PRODUCT PORTFOLIO
  • TABLE 149. ZYDUS GROUP: KEY STRATERGIES
  • TABLE 150. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 151. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 152. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 153. NOVARTIS AG: SERVICE SEGMENTS
  • TABLE 154. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 155. NOVARTIS AG: KEY STRATERGIES
  • TABLE 156. AMNEAL PHARMACEUTICALS LLC: KEY EXECUTIVES
  • TABLE 157. AMNEAL PHARMACEUTICALS LLC: COMPANY SNAPSHOT
  • TABLE 158. AMNEAL PHARMACEUTICALS LLC: PRODUCT SEGMENTS
  • TABLE 159. AMNEAL PHARMACEUTICALS LLC: SERVICE SEGMENTS
  • TABLE 160. AMNEAL PHARMACEUTICALS LLC: PRODUCT PORTFOLIO
  • TABLE 161. AMNEAL PHARMACEUTICALS LLC: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. PREGABALIN MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF PREGABALIN MARKET,2022-2032
  • FIGURE 03. TOP IMPACTING FACTORS IN PREGABALIN MARKET
  • FIGURE 04. TOP INVESTMENT POCKETS IN PREGABALIN MARKET (2023-2032)
  • FIGURE 05. BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. BARGAINING POWER OF BUYERS
  • FIGURE 07. THREAT OF SUBSTITUTION
  • FIGURE 08. THREAT OF SUBSTITUTION
  • FIGURE 09. COMPETITIVE RIVALRY
  • FIGURE 10. GLOBAL PREGABALIN MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. PREGABALIN MARKET, BY TYPE, 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF PREGABALIN MARKET FOR TABLETS AND CAPSULES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF PREGABALIN MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. PREGABALIN MARKET, BY APPLICATION, 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF PREGABALIN MARKET FOR EPILEPSY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF PREGABALIN MARKET FOR NEUROPATHIC PAIN, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF PREGABALIN MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022 AND 2032(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF PREGABALIN MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF PREGABALIN MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF PREGABALIN MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. PREGABALIN MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 23. U.S. PREGABALIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 24. CANADA PREGABALIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. MEXICO PREGABALIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. GERMANY PREGABALIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. FRANCE PREGABALIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. UK PREGABALIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. ITALY PREGABALIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. SPAIN PREGABALIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. REST OF EUROPE PREGABALIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. JAPAN PREGABALIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. CHINA PREGABALIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. INDIA PREGABALIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. AUSTRALIA PREGABALIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. SOUTH KOREA PREGABALIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. REST OF ASIA-PACIFIC PREGABALIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. BRAZIL PREGABALIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. COLOMBIA PREGABALIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. ARGENTINA PREGABALIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. REST OF LATIN AMERICA PREGABALIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. GCC PREGABALIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. SOUTH AFRICA PREGABALIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 44. NORTH AFRICA PREGABALIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 45. REST OF MIDDLE EAST AND AFRICA PREGABALIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 46. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 47. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 48. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 49. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 50. COMPETITIVE DASHBOARD
  • FIGURE 51. COMPETITIVE HEATMAP: PREGABALIN MARKET
  • FIGURE 52. TOP PLAYER POSITIONING, 2022